Imagion Biosystems
- Short interest
- 0.01%
- 0.00 pp 30d
- as of 24 Dec 2024
- Reported shorts
- 12K
- Shares on issue
- 201.341M
Imagion Biosystems (IBX) financials
Results, ratios and statements
Latest result
Half year to 30 Jun 2026 (HY26), figures in AUD, the reporting currency · Company filing, 24 Aug 2026
- Revenue
- n/avs n/a
- NPAT
- −$2.0MF (source: Company filing (extracted))vs n/a
- Company filing (extracted), as at 14 Oct 2026
- EPS (basic)
- n/avs n/a
- Rev YoY
- n/mFY
- EPS YoY
- n/aTTM
- Company filing (extracted)
Summary of Appendix 4D and Half-yearly Financial Report, 24 Aug 2026
Imagion Biosystems reported a half-year net loss of $1.98 million for the period ended 30 June 2026, a 19.2% increase from the prior year's loss of $1.66 million. No dividend was paid or declared. The company is advancing its MagSense HER2 imaging agent toward a Phase 2 clinical trial, with trial initiation expected as early as September 2026 and results anticipated in Q1 2027.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 31 Dec 2025 (FY); balance sheet at 31 Dec 2025; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- −11,074.7%
- Net margin
- −13,313.1%
- FCF margin
- −12,492.1%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- $680.3K
- Net debt / EBITDA
- n/a
- Current ratio
- 0.5×
- Interest cover
- −4.2×
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (listed unit is not one ordinary share)
- P/E
- n/a (listed unit is not one ordinary share)
- P/B
- n/a (listed unit is not one ordinary share)
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | TTM Jun 26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Revenue | n/a | $32.4KM (source: ASX (Markit)) | $1.2MM (source: ASX (Markit)) | $1.4M | $473.4K |
| Gross profit | n/a | n/a | n/a | $1.4M | $473.4K |
| Operating income | −$4.7M | −$3.6M | n/a | −$15.4M | −$12.2M |
| EBITDA | −$4.1M | −$3.5M | n/a | −$11.5M | −$8.7M |
| EBIT | −$4.1M | −$3.5M | n/a | −$12.7M | −$9.8M |
| Interest expense | $534.3K | $843.5K | n/a | $368.0K | $2.0K |
| Pretax income | −$4.6M | −$4.3M | n/a | −$13.1M | −$9.8M |
| Tax | $0 | $0 | n/a | $0 | $0 |
| NPAT | −$4.6M | −$4.3M | −$2.1MM (source: ASX (Markit)) | −$13.1M | −$9.8M |
| Net interest income | −$530.6K | −$815.2K | n/a | −$441.0K | −$144.5K |
| EPS basic | −$0.011 | −$0.015 | −$0.046 | −$0.43 | −$0.35 |
| EPS diluted | −$0.011 | −$0.015 | −$0.046 | −$0.43 | −$0.35 |
| Shares | n/a | 487.5M | 201.3M | 32.6M | 28.0M |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- Appendix 4C and Quarterly Activities Report - September 2026Quarterly Report8 Oct 2026via asx_announcements
- Appendix 4D and Half-yearly Financial ReportHalf Year Results24 Aug 2026via asx_announcements
Figures above come from this filing
- Appendix 4C and Quarterly Activities Report - June 2026Quarterly Report31 Jul 2026via asx_announcements
- Appendix 4C and Quarterly Activities Report - March 2026Quarterly Report23 Apr 2026via asx_announcements
- FY25 Appendix 4E and Annual ReportAnnual Results27 Feb 2026via asx_announcements
- Appendix 4C and Quarterly Activities Report - December 2025Quarterly Report29 Jan 2026via asx_announcements
- Appendix 4C and Quarterly Activities Report - September 2025Quarterly Report21 Oct 2025via asx_announcements
- Appendix 4D and Half-yearly Financial ReportHalf Year Results27 Aug 2025via asx_announcements
- Appendix 4C and Quarterly Activities Report - June 2025Quarterly Report29 Jul 2025via asx_announcements
- Appendix 4C and Quarterly Activities Report - March 2025Quarterly Report30 Apr 2025via asx_announcements
Showing 10 of 116 reports